Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2024; 12(5): 942-950
Published online Feb 16, 2024. doi: 10.12998/wjcc.v12.i5.942
Clinical efficacy and mechanism study of mid-frequency anti-snoring device in treating moderate obstructive sleep apnea-hypopnea syndrome
Bao Qian, Zhan-Jun Chen, Yong-Sheng Wang, Xiao-Yan Hu, Xiao-Biao Hu, Yong-Hua Zheng
Bao Qian, Zhan-Jun Chen, Xiao-Yan Hu, Xiao-Biao Hu, Yong-Hua Zheng, Pulmonary Medicine, Shanghai Jinshan Tinglin Hospital, Shanghai 201505, China
Yong-Sheng Wang, Radiology Medicine, Shanghai Jinshan Tinglin Hospital, Shanghai 201505, China
Co-first authors: Bao Qian and Zhan-Jun Chen.
Author contributions: Qian B and Chen ZJ contributed equally to this work; Qian B and Chen ZJ performed the study; Wang YS performed the computed tomography scan examination; Hu XY and Hu XB analyzed the data; Zheng YH designed the research and wrote the manuscript; all authors read and approve the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of the Shanghai Jinshan Tinglin Hospital (Approval No. 2022-06-01).
Informed consent statement: All study participants, or their legal guardian, provided informed written consent before enrollment.
Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Hua Zheng, MD, Deputy Chief Physician, Pulmonary Medicine, Shanghai Jinshan Tinglin Hospital, No. 80 North Siping Road, Jinshan District, Shanghai 201505, China. zhengyonghua0118@hotmail.com
Received: November 2, 2023
Peer-review started: November 2, 2023
First decision: December 5, 2023
Revised: December 14, 2023
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: February 16, 2024
ARTICLE HIGHLIGHTS
Research background

The mid-frequency anti-snoring device is a new technology based on sublingual nerve stimulation. Its principle is to improve the degree of oropharyngeal airway stenosis in obstructive sleep apnea-hypopnea syndrome (OSAHS) patients under mid-frequency wave stimulation.

Research motivation

There is a lack of clinical application and imaging evidence for the use of mid-frequency anti-snoring devices in the treatment of moderate OSAHS.

Research objectives

To provide imaging-based confirmation of the working mechanism of mid-frequency anti-snoring devices in treating OSAHS. This study also aimed to observe the clinical efficacy of medium-frequency anti-snoring devices in treating moderate obstructive OSAHS.

Research methods

Fifty patients diagnosed with moderate OSAHS underwent a 4-wk treatment regimen involving the mid-frequency anti-snoring device during nighttime sleep. Following the treatment, we monitored and assessed the sleep apnea quality of life index and Epworth Sleepiness Scale scores. Additionally, we performed computed tomography scans of the oropharynx in the awake state, during snoring, and while using the mid-frequency anti-snoring device. Cross-sectional area measurements in different states were taken at the narrowest airway point in the soft palate posterior and retrolingual areas.

Research results

Compared to pretreatment measurements, patients exhibited a significant reduction in the apnea-hypopnea index, the percentage of time with oxygen saturation below 90%, snoring frequency, and the duration of the most prolonged apnea event. The lowest oxygen saturation (%) showed a notable increase, and both sleep apnea quality of life index and Epworth Sleepiness Scale scores improved. Oropharyngeal computed tomography scans revealed that in OSAHS patients the cross-sectional areas of the oropharyngeal airway in the soft palate posterior area and retrolingual area decreased during snoring compared to the awake state. Conversely, during mid-frequency anti-snoring device treatment, these areas increased compared to snoring.

Research conclusions

This study confirmed that the mid-frequency anti-snoring device can expand the oropharyngeal airway in patients with moderate OSAHS, thereby improving their clinical symptoms and sleep quality.

Research perspectives

The sample size of this study was limited, and there may be statistical bias. Further efforts are needed to increase the number of patients, expand the sample size, and conduct in-depth research on some scientific issues, such as the therapeutic effect of mid-frequency anti-snoring devices on patients with only snoring, the patient dependency and efficacy of long-term use, the impact on the anatomical structure of the upper airway of the oropharynx, and the impact of long-term use on abnormal lipid metabolism in patients.